Zymeworks (FRA:ZA8) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


FRA:ZA8 Zymeworks Inc FRA:ZA8
66 GF Score
Price €20.38
GF Value €18.87
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Zymeworks Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Zymeworks's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:ZA8 vs ADMA, NRIX, IOVA: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Zymeworks's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zymeworks Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zymeworks's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Zymeworks's Margin of Safety % (DCF Earnings Based) falls into.


FRA:ZA8
66GF Score
Zymeworks Inc FRA:ZA8
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zymeworks (FRA:ZA8) Overvalued in 2026?

Based on GuruFocus' analysis, Zymeworks stock appears to be overvalued. The current stock price of €20.38 is trading 8% above its estimated GF Value™ of €18.87. GuruFocus considers Zymeworks to be Fairly Valued.

Key valuation signals for FRA:ZA8:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €18.87 vs. price of €20.38 (8% above fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the FRA:ZA8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zymeworks Business Description

Other Exchanges ZYME:USAZA8:Germany
Address 108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
66GF Score

Get the complete analysis for FRA:ZA8

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.38
Price
€18.87
GF Value